<DOC>
	<DOCNO>NCT00017342</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Combining one drug may kill cancer cell . PURPOSE : Phase II trial study effectiveness combine bryostatin 1 cytarabine treat patient relapse primary acute myelogenous leukemia .</brief_summary>
	<brief_title>Bryostatin 1 Cytarabine Treating Patients With Relapsed Acute Myelogenous Leukemia</brief_title>
	<detailed_description>OBJECTIVES : - Determine response rate patient primary acute myelogenous leukemia first relapse treat bryostatin 1 high-dose cytarabine . - Determine toxic effect regimen patient . - Determine relapse-free survival overall survival patient treat regimen . OUTLINE : This multicenter study . - Induction : Patients receive bryostatin 1 IV 24 hour day 1 11 . Patients also receive high-dose cytarabine IV 3 hour every 12 hour 4 infusion day 2-3 day 9-10 . Patients achieve major response receive second course induction therapy . - Consolidation : Patients achieve complete remission receive bryostatin 1 IV 24 hour day 1 10 high-dose cytarabine IV 3 hour every 12 hour 2 infusion day 2 9 . Treatment continue 6 course absence disease progression unacceptable toxicity . Patients achieve response subsequently relapse may receive additional induction consolidation therapy discretion investigator . Patients follow every 6 month . PROJECTED ACCRUAL : A total 15-46 patient accrue study .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Bryostatin 1</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm primary acute myelogenous leukemia ( AML ) first relapse remission least 3 month duration No secondary AML , include follow : Therapyrelated AML AML arise myelodysplastic syndrome similar hematological condition No Philadelphia chromosome evidence ( 9 ; 21 ) translocation Ineligible potentially curative allogeneic stem cell transplantation PATIENT CHARACTERISTICS : Age : 18 Performance status : Zubrod 02 Life expectancy : Not specify Hematopoietic : Not specify Hepatic : Bilirubin great 1.5 time upper limit normal ( ULN ) ( patient Gilbert 's disease unconjugated hyperbilirubinemia may bilirubin great 3.0 mg/dL conjugate bilirubin great 0.5 mg/dL ) AST/ALT great 2 time ULN Renal : Creatinine great 1.5 time ULN Pulmonary : No clinically significant pulmonary disease Other : No clinically significant cytarabinerelated cerebellar toxicity No nonmalignant systemic disease cause poor medical risk No active , uncontrolled , serious infection No medical condition would preclude study participation Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : See Disease Characteristics No prior allogeneic stem cell transplantation Chemotherapy : At least 2 week since prior systemic chemotherapy ( 24 hour hydroxyurea ) recover Endocrine therapy : Not specify Radiotherapy : Not specify Surgery : Not specify Other : Recovered prior therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2010</verification_date>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>adult acute myeloid leukemia ( 8 ; 21 ) ( q22 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 16 ; 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia inv ( 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia 11q23 ( MLL ) abnormality</keyword>
	<keyword>adult acute myeloid leukemia ( 15 ; 17 ) ( q22 ; q12 )</keyword>
</DOC>